Disease trajectories and lived experiences of patients with X-linked hypophosphatemia in Taiwan: a qualitative study.
6 affiliations
- 1Department of Pediatric Endocrinology, National Taiwan University Hospital, 100 Taipei, Taiwan.
- 2Department of Pediatric Genetics and Metabolism, Taichung Veterans General Hospital, 407219 Taichung, Taiwan.
- 3Department of Pediatric Genetics and Endocrinology, Kaohsiung Chang Gung Memorial Hospital, 833401 Kaohsiung, Taiwan.
- 4Healthcare, DKSH Management Pte. Ltd. (Asia Pacific), 329983 Singapore Singapore.
- 5Medical Affairs, Kyowa Kirin Taiwan Co., Ltd., 10448 Taipei City, Taiwan.
- 6Department of Health Economics and Outcomes Research, Kyowa Kirin International plc, SL7 1HZ Marlow, United Kingdom.
Abstract
X-linked hypophosphatemia (XLH) is a rare, lifelong disorder of renal phosphate wasting that typically presents in childhood with skeletal deformities, growth retardation, and functional impairment, although these features may be less pronounced in milder cases. The disease persists into adulthood with chronic pain, mobility limitations, and psychosocial challenges. While pediatric XLH has been well described internationally, the lifelong disease journey in Taiwan remains poorly characterized. We conducted a multicenter qualitative study using semi-structured, in-depth interviews between July 2024 and January 2025 at 3 major medical centers, enrolling 15 patients with a clinical diagnosis of XLH (genetically confirmed in a subset): 8 pediatric patients (aged ≥5 yr) interviewed with caregivers and 7 adults interviewed independently. Interviews (~60 min) explored diagnostic pathways, treatment experiences, disease burden, and support needs; transcripts were analyzed thematically. Participants commonly reported delayed or missed diagnosis, with early symptoms such as bowed legs and short stature often misattributed to nutritional or growth-related issues, leading to late referral to specialist care. Oral phosphate supplementation and active vitamin D (Pi/D) were the predominant treatments; however, frequent dosing, poor palatability, and gastrointestinal side effects contributed to low adherence. Many adults had discontinued therapy, and 12 patients underwent corrective limb surgery, mainly during childhood or adolescence. Across the life course, patients experienced chronic bone pain, reduced mobility, and insufficiency fractures, as well as psychosocial burdens, including anxiety, low self-esteem, social withdrawal, and caregiver stress, often compounded by guilt related to hereditary transmission. Patients and caregivers emphasized unmet needs in disease education, transition from pediatric to adult care, peer support, and interest in novel therapies, such as burosumab. These findings highlight substantial lifelong disease burden among patients with XLH in Taiwan and underscore the need for earlier diagnosis, multidisciplinary care, and improved access to emerging therapies.
Related
- Nurses Lived Experiences of Caring for Patients During the 2022 Ebola Virus Disease Outbreak in Uganda: A Qualitative Study
- Exploring patients’ experiences with artificial intelligence and digital health literacy in chronic disease self-management: a qualitative study
- Motivations, experiences and perspectives of physicians in Germany regarding monitoring routines in coronary heart disease and post-stroke patients: A qualitative interview study
- Healthcare professionals’ experiences of providing care for patients with Graves’ disease: a qualitative interview study in Swedish secondary care
- Experiences and perspectives of patients visiting Dutch emergency departments on opioid (mis)use: a qualitative interview study
BibTeX
@article{liu2026disease,
title = {{Disease trajectories and lived experiences of patients with X-linked hypophosphatemia in Taiwan: a qualitative study.}},
author = {Shih-Yao Liu and Yi-Ching Tung and Chia-Chi Hsu and Yu-Yuan Ke and Ying-Hua Huang and Tun-Ying Hsu and Annie Chin and Ben Johnson and Wen-Yu Tsai},
journal = {JBMR plus},
year = {2026},
month = oct,
doi = {10.1093/jbmrpl/ziag163},
url = {https://europepmc.org/article/MED/42927306},
note = {CC BY},
}
RIS
TY - JOUR
TI - Disease trajectories and lived experiences of patients with X-linked hypophosphatemia in Taiwan: a qualitative study.
AU - Shih-Yao Liu
AU - Yi-Ching Tung
AU - Chia-Chi Hsu
AU - Yu-Yuan Ke
AU - Ying-Hua Huang
AU - Tun-Ying Hsu
AU - Annie Chin
AU - Ben Johnson
AU - Wen-Yu Tsai
PY - 2026
DA - 2026/10/13
JO - JBMR plus
DO - 10.1093/jbmrpl/ziag163
UR - https://europepmc.org/article/MED/42927306
AB - X-linked hypophosphatemia (XLH) is a rare, lifelong disorder of renal phosphate wasting that typically presents in childhood with skeletal deformities, growth retardation, and functional impairment, although these features may be less pronounced in milder cases. The disease persists into adulthood with chronic pain, mobility limitations, and psychosocial challenges. While pediatric XLH has been well described internationally, the lifelong disease journey in Taiwan remains poorly characterized. We conducted a multicenter qualitative study using semi-structured, in-depth interviews between July 2024 and January 2025 at 3 major medical centers, enrolling 15 patients with a clinical diagnosis of XLH (genetically confirmed in a subset): 8 pediatric patients (aged ≥5 yr) interviewed with caregivers and 7 adults interviewed independently. Interviews (~60 min) explored diagnostic pathways, treatment experiences, disease burden, and support needs; transcripts were analyzed thematically. Participants commonly reported delayed or missed diagnosis, with early symptoms such as bowed legs and short stature often misattributed to nutritional or growth-related issues, leading to late referral to specialist care. Oral phosphate supplementation and active vitamin D (Pi/D) were the predominant treatments; however, frequent dosing, poor palatability, and gastrointestinal side effects contributed to low adherence. Many adults had discontinued therapy, and 12 patients underwent corrective limb surgery, mainly during childhood or adolescence. Across the life course, patients experienced chronic bone pain, reduced mobility, and insufficiency fractures, as well as psychosocial burdens, including anxiety, low self-esteem, social withdrawal, and caregiver stress, often compounded by guilt related to hereditary transmission. Patients and caregivers emphasized unmet needs in disease education, transition from pediatric to adult care, peer support, and interest in novel therapies, such as burosumab. These findings highlight substantial lifelong disease burden among patients with XLH in Taiwan and underscore the need for earlier diagnosis, multidisciplinary care, and improved access to emerging therapies.
SN - 2473-4039
ER -